Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484801 | 0.85 | EPHB4 (0.52) | PIK3CAPIK3R1ALDH1A1AURKA | |
| SCHEMBL5479920 | 0.84 | HIF1A (0.52) | PIK3CAPIK3R1HDAC1ALDH1A1AURKA | |
| SCHEMBL5486430 | 0.81 | EPHB4 (0.57) | PIK3CAPIK3R1AURKA | |
| SCHEMBL5483301 | 0.80 | RAF1 (0.50) | PIK3CAPIK3R1ALDH1A1AURKA | |
| SCHEMBL12752989 | 0.74 | HRH3 (0.67) | HRH3PARP1ALDH1A1TSHRDYRK1A | |
| SCHEMBL5477740 | 0.72 | AURKA (0.52) | PIK3CAPIK3R1ALDH1A1TSHRAURKA | |
| SCHEMBL1419912 | 0.72 | DHODH (0.61) | HRH3PARP1ALDH1A1 | |
| SCHEMBL5481483 | 0.71 | EPHB4 (0.57) | AURKA | |
| SCHEMBL5485686 | 0.71 | EPHB4 (0.55) | PIK3CAPIK3R1AURKA | |
| SCHEMBL12828981 | 0.69 | PARP1 (0.49) | HRH3PARP1ALDH1A1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160885-B2 | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | CGI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | claimed |
| US-20050054649-A1 | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity | XEROX CORPORATION | 2005-03-10 | — | — | US | claimed |
| US-7160885-B2 | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | CGI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160885-B2 | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | CGI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160885-B2 | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | CGI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050054649-A1 | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity | XEROX CORPORATION | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054649-A1 | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity | HSP90AB1, HSP90AA1, HSPA9 | PIK3CA 3362/4885PIK3R1 2072/4885HRH3 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.